| P/E (FY) | — | Sales (TTM) | $285.6M |
| Earnings (TTM) | -$353.9M | ROE | −55.50% |
| Net Margin | −148.38% | ROIC | −80.85% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies using autologous tumor infiltrating lymphocytes for metastatic melanoma and other solid tumor cancers in the United States and internationally. It markets Amtagvi, an individualized T cell therapy for advanced melanoma, and Proleukin, an interleukin-2 product for metastatic melanoma and renal cell carcinoma. It is also developing lifileucel for melanoma, cervical, lung, endometrial, and head and neck cancers.
| Market Cap | $2.10B | Trading Days | 3960 |
| 52W High | 5.64 |
| 52W Low | 1.76 |
| % Off High | −16.67% |
| YTD | 72.16% | 1Y | 59.32% |
| 3Y | −34.72% | 5Y | −79.49% |
| 10Y | −45.48% | Since incept. (ann.) | −18.11% |
Single Reportable 100%
| Ann. Volatility (1Y) | 94.80% | Ann. Volatility (3Y) | 95.89% |
| Sharpe (1Y) | 0.96 | Sharpe (3Y) | 0.34 |
| Max Drawdown (1Y) | −39.00% | Max Drawdown (3Y) | −90.50% |
| Beta (3Y, vs SPY) | 2.15 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ADMA | ADMA BIOLOGICS, INC. | $2.04B | 14.6 |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.35B | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.86B | — |
| VCEL | Vericel Corp | $2.39B | 146.0 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.48B | 8.0 |
| KOD | Kodiak Sciences Inc. | $2.52B | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.54B | — |
| IMCR | Immunocore Holdings plc | $1.70B | — |
| BEAM | Beam Therapeutics Inc. | $2.70B | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.57B | — |
| MAZE | Maze Therapeutics, Inc. | $1.54B |
| VIR | Vir Biotechnology, Inc. | $1.49B | — |
